Cancer treatment and survivorship statistics, 2022

Kimberly D Miller, Leticia Nogueira, Theresa Devasia, Angela B Mariotto, K Robin Yabroff, Ahmedin Jemal, Joan Kramer, Rebecca L Siegel, Kimberly D Miller, Leticia Nogueira, Theresa Devasia, Angela B Mariotto, K Robin Yabroff, Ahmedin Jemal, Joan Kramer, Rebecca L Siegel

Abstract

The number of cancer survivors continues to increase in the United States due to the growth and aging of the population as well as advances in early detection and treatment. To assist the public health community in better serving these individuals, the American Cancer Society and the National Cancer Institute collaborate triennially to estimate cancer prevalence in the United States using incidence and survival data from the Surveillance, Epidemiology, and End Results cancer registries, vital statistics from the Centers for Disease Control and Prevention's National Center for Health Statistics, and population projections from the US Census Bureau. Current treatment patterns based on information in the National Cancer Database are presented for the most prevalent cancer types by race, and cancer-related and treatment-related side-effects are also briefly described. More than 18 million Americans (8.3 million males and 9.7 million females) with a history of cancer were alive on January 1, 2022. The 3 most prevalent cancers are prostate (3,523,230), melanoma of the skin (760,640), and colon and rectum (726,450) among males and breast (4,055,770), uterine corpus (891,560), and thyroid (823,800) among females. More than one-half (53%) of survivors were diagnosed within the past 10 years, and two-thirds (67%) were aged 65 years or older. One of the largest racial disparities in treatment is for rectal cancer, for which 41% of Black patients with stage I disease receive proctectomy or proctocolectomy compared to 66% of White patients. Surgical receipt is also substantially lower among Black patients with non-small cell lung cancer, 49% for stages I-II and 16% for stage III versus 55% and 22% for White patients, respectively. These treatment disparities are exacerbated by the fact that Black patients continue to be less likely to be diagnosed with stage I disease than White patients for most cancers, with some of the largest disparities for female breast (53% vs 68%) and endometrial (59% vs 73%). Although there are a growing number of tools that can assist patients, caregivers, and clinicians in navigating the various phases of cancer survivorship, further evidence-based strategies and equitable access to available resources are needed to mitigate disparities for communities of color and optimize care for people with a history of cancer. CA Cancer J Clin. 2022;72:409-436.

Keywords: prevalence; statistics; survivorship; treatment patterns.

© 2022 The Authors. CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society.

References

    1. Weaver KE, Forsythe LP, Reeve BB, et al. Mental and physical health-related quality of life among U.S. cancer survivors: population estimates from the 2010 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev. 2012;21:2108-2117.
    1. Berry LL, Davis SW, Godfrey Flynn A, Landercasper J, Deming KA. Is it time to reconsider the term “cancer survivor?” J Psychosoc Oncol. 2019;37:413-426.
    1. Verdecchia A, De Angelis G, Capocaccia R. Estimation and projections of cancer prevalence from cancer registry data. Stat Med. 2002;21:3511-3526.
    1. Surveillance Research Program, National Cancer Institute. SEER*Stat software, version 8.3.9. National Cancer Institute; 2021.
    1. Surveillance Research Program, National Cancer Institute. SEER*Stat software, version 8.3.5. National Cancer Institute; 2018.
    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7-33.
    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: North American Association of Central Cancer Registries Incidence-Cancer in North America Analytic File, 1995-2018, with Race/Ethnicity, Custom File With County, American Cancer Society Facts and Figures Projection Project. North American Association of Central Cancer Registries; 2019
    1. Liu B, Zhu L, Zou J, et al. Updated methodology for projecting U.S.- and state-level cancer counts for the current calendar year: part I: spatio-temporal modeling for cancer incidence. Cancer Epidemiol Biomarkers Prev. 2021;30(9):1620-1626.
    1. Miller KD, Siegel RL, Liu B, et al. Updated methodology for projecting U.S.- and state-level cancer counts for the current calendar year: part II: evaluation of incidence and mortality projection methods. Cancer Epidemiol Biomarkers Prev. 2021;30(11):1993-2000.
    1. American Joint Committee on Cancer (AJCC). AJCC Cancer Staging Manual. 7th ed. Springer; 2010.
    1. Howlader N, Noone AM & Krapcho M et al, eds. SEER Cancer Statistics Review, 1975-2018. National Cancer Institute; 2021. Accessed March 30, 2022.
    1. American College of Surgeons, Commission on Cancer. National Cancer Database. 2019 Data Submission. American College of Surgeons; 2021.
    1. Mallin K, Browner A, Palis B, et al. Incident cases captured in the National Cancer Database compared with those in U.S. population based central cancer registries in 2012-2014. Ann Surg Oncol. 2019;26:1604-1612.
    1. Mariotto AB, Etzioni R, Hurlbert M, Penberthy L, Mayer M. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2017;26:809-815.
    1. Jatoi I, Proschan MA. Randomized trials of breast-conserving therapy versus mastectomy for primary breast cancer: a pooled analysis of updated results. Am J Clin Oncol. 2005;28:289-294. doi:00000421-200506000-00013
    1. Litiere S, Werutsky G, Fentiman IS, et al. Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol. 2012;13:412-419.
    1. Gradishar WJ, Anderson BO, Balassanian R, et al. Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16:310-320.
    1. Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM, on behalf of the PRIME II investigators. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015;16:266-273.
    1. Kummerow KL, Du L, Penson DF, Shyr Y, Hooks MA. Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg. 2015;150:9-16.
    1. Albornoz CR, Matros E, Lee CN, et al. Bilateral mastectomy versus breast-conserving surgery for early-stage breast cancer: the role of breast reconstruction. Plast Reconstr Surg. 2015;135:1518-1526.
    1. Montagna G, Morrow M. Contralateral prophylactic mastectomy in breast cancer: what to discuss with patients. Expert Rev Anticancer Ther. 2020;20:159-166.
    1. Lautner M, Lin H, Shen Y, et al. Disparities in the use of breast-conserving therapy among patients with early-stage breast cancer. JAMA Surg. 2015;150:778-786.
    1. Freedman RA, Virgo KS, Labadie J, He Y, Partridge AH, Keating NL. Receipt of locoregional therapy among young women with breast cancer. Breast Cancer Res Treat. 2012;135:893-906.
    1. Wang T, Baskin AS, Dossett LA. Deimplementation of the Choosing Wisely recommendations for low-value breast cancer surgery: a systematic review. JAMA Surg. 2020;155:759-770.
    1. Nash R, Goodman M, Lin CC, et al. State variation in the receipt of a contralateral prophylactic mastectomy among women who received a diagnosis of invasive unilateral early-stage breast cancer in the United States, 2004-2012. JAMA Surg. 2017;152:648-657.
    1. Baskin AS, Wang T, Bredbeck BC, Sinco BR, Berlin NL, Dossett LA. Trends in contralateral prophylactic mastectomy utilization for small unilateral breast cancer. J Surg Res. 2021;262:71-84.
    1. Basu NN, Hodson J, Chatterjee S, et al. The Angelina Jolie effect: contralateral risk-reducing mastectomy trends in patients at increased risk of breast cancer. Sci Rep. 2021;11:2847.
    1. Guth U, Myrick ME, Viehl CT, Weber WP, Lardi AM, Schmid SM. Increasing rates of contralateral prophylactic mastectomy-a trend made in USA? Eur J Surg Oncol. 2012;38:296-301.
    1. Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810-821.
    1. Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529-1541.
    1. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523-533.
    1. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753-763.
    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 9 Registries Research Data, November 2020 Submission (1973-2018) <Katrina/Rita Population Adjustment>-Linked To County Attributes-Total United States, 1969-2019 Counties. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2021.
    1. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784-1792.
    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 18 Registries Research Data + Hurricane Katrina Impacted Louisiana Cases, November 2020 Submission (2000-2018) <Katrina/Rita Population Adjustment>-Linked To County Attributes-Total United States, 1969-2019 Counties. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2021.
    1. Jemal A, Robbins AS, Lin CC, et al. Factors that contributed to black-white disparities in survival among nonelderly women with breast cancer between 2004 and 2013. J Clin Oncol. 2018;36:14-24.
    1. Ellis L, Canchola AJ, Spiegel D, Ladabaum U, Haile R, Gomez SL. Racial and ethnic disparities in cancer survival: the contribution of tumor, sociodemographic, institutional, and neighborhood characteristics. J Clin Oncol. 2018;36:25-33.
    1. DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69:438-451.
    1. Lorona NC, Malone KE, Li CI. Racial/ethnic disparities in risk of breast cancer mortality by molecular subtype and stage at diagnosis. Breast Cancer Res Treat. 2021;190:549-558.
    1. McLaughlin SA, Brunelle CL, Taghian A. Breast cancer-related lymphedema: risk factors, screening, management, and the impact of locoregional treatment. J Clin Oncol. 2020;38:2341-2350.
    1. DiSipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013;14:500-515.
    1. Rafn BS, Christensen J, Larsen A, Bloomquist K. Prospective surveillance for breast cancer-related arm lymphedema: a systematic review and meta-analysis. J Clin Oncol. 2022;40:1009-1026.
    1. Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. J Clin Oncol. 2016;34:611-635.
    1. Paramanandam VS, Dylke E, Clark GM, et al. Prophylactic use of compression sleeves reduces the incidence of arm swelling in women at high risk of breast cancer-related lymphedema: a randomized controlled trial. J Clin Oncol. Published online February 2, 2022.
    1. Stubblefield MD. The underutilization of rehabilitation to treat physical impairments in breast cancer survivors. PM R. 2017;9(9 suppl 2):S317-S323.
    1. Wang K, Yee C, Tam S, et al. Prevalence of pain in patients with breast cancer post-treatment: a systematic review. Breast. 2018;42:113-127.
    1. Wang L, Guyatt GH, Kennedy SA, et al. Predictors of persistent pain after breast cancer surgery: a systematic review and meta-analysis of observational studies. CMAJ. 2016;188:E352-E361.
    1. Carter J, Lacchetti C, Andersen BL, et al. Interventions to address sexual problems in people with cancer: American Society of Clinical Oncology clinical practice guideline adaptation of Cancer Care Ontario guideline. J Clin Oncol. 2018;36:492-511.
    1. Rosenberg SM, Dominici LS, Gelber S, et al. Association of breast cancer surgery with quality of life and psychosocial well-being in young breast cancer survivors. JAMA Surg. 2020;155:1035-1042.
    1. Schover LR, van der Kaaij M, van Dorst E, Creutzberg C, Huyghe E, Kiserud CE. Sexual dysfunction and infertility as late effects of cancer treatment. EJC Suppl. 2014;12:41-53.
    1. Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36:1994-2001.
    1. Howard-Anderson J, Ganz PA, Bower JE, Stanton AL. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J Natl Cancer Inst. 2012;104:386-405.
    1. Letourneau JM, Wald K, Sinha N, et al. Fertility preservation before breast cancer treatment appears unlikely to affect disease-free survival at a median follow-up of 43 months after fertility-preservation consultation. Cancer. 2020;126:487-495.
    1. Rodriguez-Wallberg KA, Eloranta S, Krawiec K, Lissmats A, Bergh J, Liljegren A. Safety of fertility preservation in breast cancer patients in a register-based matched cohort study. Breast Cancer Res Treat. 2018;167:761-769.
    1. Greer AC, Lanes A, Poorvu PD, et al. The impact of fertility preservation on the timing of breast cancer treatment, recurrence, and survival. Cancer. 2021;127:3872-3880.
    1. Williams AM, Khan CP, Heckler CE, et al. Fatigue, anxiety, and quality of life in breast cancer patients compared to non-cancer controls: a nationwide longitudinal analysis. Breast Cancer Res Treat. 2021;187:275-285.
    1. Rivera E, Cianfrocca M. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol. 2015;75:659-670.
    1. Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol. 2012;23(suppl 7):vii155-vii166.
    1. Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017;35:893-911.
    1. Conte P, Frassoldati A. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: putting safety issues into perspective. Breast J. 2007;13:28-35.
    1. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987-998.
    1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771-784.
    1. Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013;381:1827-1834.
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7-30.
    1. Kannarkatt J, Joseph J, Kurniali PC, Al-Janadi A, Hrinczenko B. Adjuvant chemotherapy for stage II colon cancer: a clinical dilemma. J Oncol Pract. 2017;13:233-241.
    1. Sonbol MB, Mountjoy LJ, Firwana B, et al. The role of maintenance strategies in metastatic colorectal cancer: a systematic review and network meta-analysis of randomized clinical trials. JAMA Oncol. 2020;6:e194489.
    1. Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325:669-685.
    1. Hao S, Snyder RA, Irish W, Parikh AA. Association of race and health insurance in treatment disparities of colon cancer: a retrospective analysis utilizing a national population database in the United States. PLoS Med. 2021;18:e1003842.
    1. Murphy CC, Harlan LC, Warren JL, Geiger AM. Race and insurance differences in the receipt of adjuvant chemotherapy among patients with stage III colon cancer. J Clin Oncol. 2015;33:2530-2536.
    1. Shahjehan F, Kasi PM, Habermann E, et al. Trends and outcomes of sphincter-preserving surgery for rectal cancer: a National Cancer Database study. Int J Colorectal Dis. 2019;34:239-245.
    1. Arsoniadis EG, Fan Y, Jarosek S, et al. Decreased use of sphincter-preserving procedures among African Americans with rectal cancer. Ann Surg Oncol. 2018;25:720-728.
    1. Sineshaw HM, Ng K, Flanders WD, Brawley OW, Jemal A. Factors that contribute to differences in survival of Black vs White patients with colorectal cancer. Gastroenterology. 2018;154:906-915.e7.
    1. Gebremedhn EG, Shortland PJ, Mahns DA. The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: a systematic review. BMC Cancer. 2018;18:410.
    1. Iveson TJ, Sobrero AF, Yoshino T, et al. Duration of adjuvant doublet chemotherapy (3 or 6 months) in patients with high-risk stage II colorectal cancer. J Clin Oncol. 2021;39:631-641.
    1. Grothey A, Sobrero AF, Shields AF, et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med. 2018;378:1177-1188.
    1. Keefe DM, Elting LS, Nguyen HT, et al. Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy. Cancer Chemother Pharmacol. 2014;74:675-680.
    1. Denlinger CS, Barsevick AM. The challenges of colorectal cancer survivorship. J Natl Compr Canc Netw. 2009;7:883-893; quiz 894.
    1. Emmertsen KJ, Laurberg S, Rectal Cancer Function Study Group. Impact of bowel dysfunction on quality of life after sphincter-preserving resection for rectal cancer. Br J Surg. 2013;100:1377-1387.
    1. Lange MM, Martz JE, Ramdeen B, et al. Long-term results of rectal cancer surgery with a systematical operative approach. Ann Surg Oncol. 2013;20:1806-1815.
    1. Den Oudsten BL, Traa MJ, Thong MS, et al. Higher prevalence of sexual dysfunction in colon and rectal cancer survivors compared with the normative population: a population-based study. Eur J Cancer. 2012;48:3161-3170.
    1. Liu L, Herrinton LJ, Hornbrook MC, Wendel CS, Grant M, Krouse RS. Early and late complications among long-term colorectal cancer survivors with ostomy or anastomosis. Dis Colon Rectum. 2010;53:200-212.
    1. Averyt JC, Nishimoto PW. Addressing sexual dysfunction in colorectal cancer survivorship care. J Gastrointest Oncol. 2014;5:388-394.
    1. Sun V, Grant M, Wendel CS, et al. Sexual function and health-related quality of life in long-term rectal cancer survivors. J Sex Med. 2016;13:1071-1079.
    1. El-Shami K, Oeffinger KC, Erb NL, et al. American Cancer Society colorectal cancer survivorship care guidelines. CA Cancer J Clin. 2015;65:427-455.
    1. Holowatyj AN, Eng C, Lewis MA. Incorporating reproductive health in the clinical management of early-onset colorectal cancer. JCO Oncol Pract. 2022;18:169-172.
    1. Yilmaz M, Kantarjian H, Ravandi F. Acute promyelocytic leukemia current treatment algorithms. Blood Cancer J. 2021;11:123.
    1. Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136-1152.
    1. Appelbaum FR, Bernstein ID. Gemtuzumab ozogamicin for acute myeloid leukemia. Blood. 2017;130:2373-2376.
    1. Cucchi DGJ, Polak TB, Ossenkoppele GJ, et al. Two decades of targeted therapies in acute myeloid leukemia. Leukemia. 2021;35:651-660.
    1. Etienne G, Guilhot J, Rea D, et al. Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;35:298-305.
    1. Schoenbeck KL, Atallah E, Lin L, et al. Patient-reported functional outcomes in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors. J Natl Cancer Inst. 2022;114:160-164.
    1. DeAngelo DJ, Stevenson KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015;29:526-534.
    1. Mrozek K, Harper DP, Aplan PD. Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009;23:991-1010.
    1. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013;381:1943-1955.
    1. Dai H, Wang Y, Lu X, Han W. Chimeric antigen receptors modified T-cells for cancer therapy. J Natl Cancer Inst. 2016;108:djv439.
    1. Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425-2437.
    1. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370:1101-1110.
    1. Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015;385:1873-1883.
    1. Jain P, O'Brien S. Richter's transformation in chronic lymphocytic leukemia. Oncology (Williston Park). 2012;26:1146-1152.
    1. Alonso C, Dutta SW, Mitra N, et al. Adult nodular lymphocyte-predominant Hodgkin lymphoma: treatment modality utilization and survival. Cancer Med. 2018;7:1118-1126.
    1. Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. N Engl J Med. 2018;378:331-344.
    1. Ansell SM. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018;93:704-715.
    1. Coiffier B. State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol. 2005;23:6387-6393.
    1. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998;339:21-26.
    1. Vargo JA, Gill BS, Balasubramani GK, Beriwal S. Treatment selection and survival outcomes in early-stage diffuse large B-cell lymphoma: do we still need consolidative radiotherapy? J Clin Oncol. 2015;33:3710-3717.
    1. Shankland KR, Armitage JO, Hancock BW. Non-Hodgkin lymphoma. Lancet. 2012;380:848-857.
    1. Socie G, Ritz J. Current issues in chronic graft-versus-host disease. Blood. 2014;124:374-384.
    1. Ng AK, Mauch PM. Late effects of Hodgkin's disease and its treatment. Cancer J. 2009;15:164-168.
    1. van Nimwegen FA, Schaapveld M, Janus CP, et al. Risk of diabetes mellitus in long-term survivors of Hodgkin lymphoma. J Clin Oncol. 2014;32:3257-3263.
    1. Nathan PC, Patel SK, Dilley K, et al. Guidelines for identification of, advocacy for, and intervention in neurocognitive problems in survivors of childhood cancer: a report from the Children's Oncology Group. Arch Pediatr Adolesc Med. 2007;161:798-806.
    1. Merritt RE, Abdel-Rasoul M, D'Souza DM, Kneuertz PJ. Racial disparities in overall survival and surgical treatment for early stage lung cancer by facility type. Clin Lung Cancer. 2021;22:e691-e698.
    1. Ezer N, Mhango G, Bagiella E, Goodman E, Flores R, Wisnivesky JP. Racial disparities in resection of early stage non-small cell lung cancer: variability among surgeons. Med Care. 2020;58:392-398.
    1. Jones GS, Baldwin DR. Recent advances in the management of lung cancer. Clin Med (Lond). 2018;18(suppl 2):s41-s46.
    1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7-33.
    1. Horn L, Mansfield AS, Szczesna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220-2229.
    1. American College of Surgeons Commission on Cancer. National Cancer Database, 2016 data submission. American College of Surgeons; 2019.
    1. Poghosyan H, Sheldon LK, Leveille SG, Cooley ME. Health-related quality of life after surgical treatment in patients with non-small cell lung cancer: a systematic review. Lung Cancer. 2013;81:11-26.
    1. Chambers SK, Dunn J, Occhipinti S, et al. A systematic review of the impact of stigma and nihilism on lung cancer outcomes. BMC Cancer. 2012;12:184.
    1. Karam-Hage M, Cinciripini PM, Gritz ER. Tobacco use and cessation for cancer survivors: an overview for clinicians. CA Cancer J Clin. 2014;64:272-290.
    1. Sitas F, Weber MF, Egger S, Yap S, Chiew M, O'Connell D. Smoking cessation after cancer. J Clin Oncol. 2014;32:3593-3595.
    1. Gemine RE, Ghosal R, Collier G, et al. Longitudinal study to assess impact of smoking at diagnosis and quitting on 1-year survival for people with non-small cell lung cancer. Lung Cancer. 2019;129:1-7.
    1. Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377:1813-1823.
    1. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824-1835.
    1. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789-1801.
    1. Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386:24-34.
    1. Karimkhani C, Gonzalez R, Dellavalle RP. A review of novel therapies for melanoma. Am J Clin Dermatol. 2014;15:323-337.
    1. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23-34.
    1. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521-2532.
    1. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30-39.
    1. Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ. 2005;331:481.
    1. Farrow NE, Turner MC, Salama AKS, Beasley GM. Overall survival improved for contemporary patients with melanoma: a 2004-2015 National Cancer Database analysis. Oncol Ther. 2020;8:261-275.
    1. Balamurugan A, Rees JR, Kosary C, Rim SH, Li J, Stewart SL. Subsequent primary cancers among men and women with in situ and invasive melanoma of the skin. J Am Acad Dermatol. 2011;65(5 suppl 1):S69-S77.
    1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
    1. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158-168.
    1. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
    1. Carlos G, Anforth R, Clements A, et al. Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma. JAMA Dermatol. 2015;151:1103-1109.
    1. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293:2095-2101.
    1. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009;302:1202-1209.
    1. Shappley WV 3rd, Kenfield SA, Kasperzyk JL, et al. Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol. 2009;27:4980-4985.
    1. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer, Version 1.2010. NCCN; 2010.
    1. Mahal BA, Butler S, Franco I, et al. Use of active surveillance or watchful waiting for low-risk prostate cancer and management trends across risk groups in the United States, 2010-2015. JAMA. 2019;321:704-706.
    1. Cooperberg MR, Carroll PR. Trends in management for patients with localized prostate cancer, 1990-2013. JAMA. 2015;314:80-82.
    1. Nocera L, Wenzel M, Colla Ruvolo C, et al. The effect of race/ethnicity on active treatment rates among septuagenarian or older low risk prostate cancer patients. Urol Oncol. 2021;39:785.e11-785.e17.
    1. Liu Y, Hall IJ, Filson C, Howard DH. Trends in the use of active surveillance and treatments in Medicare beneficiaries diagnosed with localized prostate cancer. Urol Oncol. 2021;39:432.e1-432.e10.
    1. Washington SL 3rd, Jeong CW, Lonergan PE, et al. Regional variation in active surveillance for low-risk prostate cancer in the US. JAMA Netw Open. 2020;3:e2031349.
    1. Presley CJ, Raldow AC, Cramer LD, et al. A new approach to understanding racial disparities in prostate cancer treatment. J Geriatr Oncol. 2013;4:1-8.
    1. Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091-1103.
    1. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424-433.
    1. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138-148.
    1. Alicikus ZA, Yamada Y, Zhang Z, et al. Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer. 2011;117:1429-1437.
    1. Birkhahn M, Penson DF, Cai J, et al. Long-term outcome in patients with a Gleason score ≤6 prostate cancer treated by radical prostatectomy. BJU Int. 2011;108:660-664.
    1. Nam RK, Cheung P, Herschorn S, et al. Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. Lancet Oncol. 2014;15:223-231.
    1. Resnick MJ, Koyama T, Fan KH, et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013;368:436-445.
    1. Taylor KL, Luta G, Miller AB, et al. Long-term disease-specific functioning among prostate cancer survivors and noncancer controls in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. J Clin Oncol. 2012;30:2768-2775.
    1. Nguyen C, Lairson DR, Swartz MD, Du XL. Risks of major long-term side effects associated with androgen-deprivation therapy in men with prostate cancer. Pharmacotherapy. 2018;38:999-1009.
    1. Mitchell AP, Mishra A, Panageas KS, Lipitz-Snyderman A, Bach PB, Morris MJ. Real-world use of bone modifying agents in metastatic castration-sensitive prostate cancer. J Natl Cancer Inst. 2022;114:419-426.
    1. Levine GN, D'Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin. 2010;60:194-201.
    1. Skolarus TA, Wolf AM, Erb NL, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin. 2014;64:225-249.
    1. Butler SS, Mahal BA, Moslehi JJ, et al. Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: a secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized controlled trial. Cancer. 2021;127:2213-2221.
    1. Leung E, Warde P, Jewett M, et al. Treatment burden in stage I seminoma: a comparison of surveillance and adjuvant radiation therapy. BJU Int. 2013;112:1088-1095.
    1. Parekh NV, Lundy SD, Vij SC. Fertility considerations in men with testicular cancer. Transl Androl Urol. 2020;9(suppl 1):S14-S23.
    1. Willemse PM, Burggraaf J, Hamdy NA, et al. Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors. Br J Cancer. 2013;109:60-67.
    1. Fung C, Dinh PC, Fossa SD, Travis LB. Testicular cancer survivorship. J Natl Compr Canc Netw. 2019;17:1557-1568.
    1. Pitt SC, Moley JF. Medullary, anaplastic, and metastatic cancers of the thyroid. Semin Oncol. 2010;37:567-579.
    1. Haymart MR, Banerjee M, Stewart AK, Koenig RJ, Birkmeyer JD, Griggs JJ. Use of radioactive iodine for thyroid cancer. JAMA. 2011;306:721-728.
    1. Leboulleux S, Bournaud C, Chougnet CN, et al. Thyroidectomy without radioiodine in patients with low-risk thyroid cancer. N Engl J Med. 2022;386:923-932.
    1. Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25:567-610.
    1. Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36:7-13.
    1. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1-133.
    1. Clement SC, Peeters RP, Ronckers CM, et al. Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma-a systematic review. Cancer Treat Rev. 2015;41:925-934.
    1. Marti JL, Jain KS, Morris LG. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer. Thyroid. 2015;25:681-687.
    1. Santoro M, Carlomagno F. Central role of RET in thyroid cancer. Cold Spring Harb Perspect Biol. 2013;5:a009233.
    1. Khanna A, Yerram N, Zhu H, Kim S, Abouassaly R. Utilization of Bacillus Calmette-Guerin for nonmuscle invasive bladder cancer in an era of Bacillus Calmette-Guerin supply shortages. Urology. 2019;124:120-126.
    1. Cheung G, Sahai A, Billia M, Dasgupta P, Khan MS. Recent advances in the diagnosis and treatment of bladder cancer. BMC Med. 2013;11:13.
    1. Mak RH, Hunt D, Shipley WU, et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014;32:3801-3809.
    1. Mitin T, Hunt D, Shipley WU, et al. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol. 2013;14:863-872.
    1. Marinaro J, Zeymo A, Egan J, et al. Sex and racial disparities in the treatment and outcomes of muscle-invasive bladder cancer. Urology. 2021;151:154-162.
    1. Heney NM, Ahmed S, Flanagan MJ, et al. Superficial bladder cancer: progression and recurrence. J Urol. 1983;130:1083-1086.
    1. Lutzeyer W, Rubben H, Dahm H. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol. 1982;127:250-252.
    1. Chamie K, Litwin MS, Bassett JC, et al. Recurrence of high-risk bladder cancer: a population-based analysis. Cancer. 2013;119:3219-3227.
    1. Lee RK, Abol-Enein H, Artibani W, et al. Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. BJU Int. 2014;113:11-23.
    1. Roghmann F, Becker A, Trinh QD, et al. Updated assessment of neobladder utilization and morbidity according to urinary diversion after radical cystectomy: a contemporary US-population-based cohort. Can Urol Assoc J. 2013;7:E552-E560.
    1. Kaspers M, Llamocca E, Quick A, Dholakia J, Salani R, Felix AS. Black and Hispanic women are less likely than white women to receive guideline-concordant endometrial cancer treatment. Am J Obstet Gynecol. 2020;223:398.e1-398.e18.
    1. Dholakia J, Llamocca E, Quick A, Salani R, Felix AS. Guideline-concordant treatment is associated with improved survival among women with non-endometrioid endometrial cancer. Gynecol Oncol. 2020;157:716-722.
    1. Felix AS, Cohn DE, Brasky TM, et al. Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 study. Am J Obstet Gynecol. 2018;219:459.e1-459.e11.
    1. Saris DH, Smith AJB, Brensinger C, et al. Disparities in cancer-specific and overall survival in Black women with endometrial cancer: a Medicare-SEER study. Gynecol Oncol Rep. 2022;40:100922.
    1. Corey L, Cote ML, Ruterbusch JJ, Vezina A, Winer I. Disparities in adjuvant treatment of high-grade endometrial cancer in the Medicare population. Am J Obstet Gynecol. 2022;226:541.e1-542.e13.
    1. Fedewa SA, Lerro C, Chase D, Ward EM. Insurance status and racial differences in uterine cancer survival: a study of patients in the National Cancer Database. Gynecol Oncol. 2011;122:63-68.
    1. Clarke MA, Devesa SS, Harvey SV, Wentzensen N. Hysterectomy-corrected uterine corpus cancer incidence trends and differences in relative survival reveal racial disparities and rising rates of nonendometrioid cancers. J Clin Oncol. 2019;37:1895-1908.
    1. Wright JD, Buck AM, Shah M, Burke WM, Schiff PB, Herzog TJ. Safety of ovarian preservation in premenopausal women with endometrial cancer. J Clin Oncol. 2009;27:1214-1219.
    1. Audette C, Waterman J. The sexual health of women after gynecologic malignancy. J Midwifery Womens Health. 2010;55:357-362.
    1. Yost KJ, Cheville AL, Al-Hilli MM, et al. Lymphedema after surgery for endometrial cancer: prevalence, risk factors, and quality of life. Obstet Gynecol. 2014;124(2 pt 1):307-315.
    1. Phillips SM, Padgett LS, Leisenring WM, et al. Survivors of childhood cancer in the United States: prevalence and burden of morbidity. Cancer Epidemiol Biomarkers Prev. 2015;24:653-663.
    1. Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21:774-780.
    1. Parsons HM, Harlan LC, Seibel NL, Stevens JL, Keegan TH. Clinical trial participation and time to treatment among adolescents and young adults with cancer: does age at diagnosis or insurance make a difference? J Clin Oncol. 2011;29:4045-4053.
    1. Bleyer A. Young adult oncology: the patients and their survival challenges. CA Cancer J Clin. 2007;57:242-255.
    1. Armstrong GT, Chen Y, Yasui Y, et al. Reduction in late mortality among 5-year survivors of childhood cancer. N Engl J Med. 2016;374:833-842.
    1. Meadows AT, Friedman DL, Neglia JP, et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol. 2009;27:2356-2362.
    1. Armstrong GT, Kawashima T, Leisenring W, et al. Aging and risk of severe, disabling, life-threatening, and fatal events in the Childhood Cancer Survivor Study. J Clin Oncol. 2014;32:1218-1227.
    1. Bates JE, Howell RM, Liu Q, et al. Therapy-related cardiac risk in childhood cancer survivors: an analysis of the Childhood Cancer Survivor Study. J Clin Oncol. 2019;37:1090-1101.
    1. Armstrong GT, Oeffinger KC, Chen Y, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol. 2013;31:3673-3680.
    1. Hudson MM, Ness KK, Gurney JG, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013;309:2371-2381.
    1. Castellino SM, Ullrich NJ, Whelen MJ, Lange BJ. Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors. J Natl Cancer Inst. 2014;106:dju186.
    1. Barton SE, Najita JS, Ginsburg ES, et al. Infertility, infertility treatment, and achievement of pregnancy in female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2013;14:873-881.
    1. Wasilewski-Masker K, Seidel KD, Leisenring W, et al. Male infertility in long-term survivors of pediatric cancer: a report from the Childhood Cancer Survivor Study. J Cancer Res Pract. 2014;8:437-447.
    1. Chow EJ, Stratton KL, Leisenring WM, et al. Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2016;17:567-576.
    1. Green DM, Sklar CA, Boice JD Jr, et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27:2374-2381.
    1. Zgardau A, Ray JG, Baxter NN, et al. Obstetrical and perinatal outcomes in female survivors of childhood and adolescent cancer: a population-based cohort study. J Natl Cancer Inst. 2022;114:553-564.
    1. Chow EJ, Ness KK, Armstrong GT, et al. Current and coming challenges in the management of the survivorship population. Semin Oncol. 2020;47:23-39.
    1. Barr RD, Ferrari A, Ries L, Whelan J, Bleyer WA. Cancer in adolescents and young adults: a narrative review of the current status and a view of the future. JAMA Pediatr. 2016;170:495-501.
    1. Gurney JG, Krull KR, Kadan-Lottick N, et al. Social outcomes in the Childhood Cancer Survivor Study cohort. J Clin Oncol. 2009;27:2390-2395.
    1. Bailey ZD, Feldman JM, Bassett MT. How structural racism works-racist policies as a root cause of U.S. racial health inequities. N Engl J Med. 2021;384:768-773.
    1. Freedman RA, Ruddy KJ. Who are the patients in our clinical trials for cancer? J Clin Oncol. 2019;37:1519-1523.
    1. Bitterman DS, Bona K, Laurie F, et al. Race disparities in proton radiotherapy use for cancer treatment in patients enrolled in Children's Oncology Group trials. JAMA Oncol. 2020;6:1465-1468.
    1. Lee Smith J, Hall IJ. Advancing health equity in cancer survivorship: opportunities for public health. Am J Prev Med. 2015;49(6 suppl 5):S477-S482.
    1. Bowen DJ, Alfano CM, McGregor BA, et al. Possible socioeconomic and ethnic disparities in quality of life in a cohort of breast cancer survivors. Breast Cancer Res Treat. 2007;106:85-95.
    1. Brawarsky P, Neville BA, Fitzmaurice GM, Earle C, Haas JS. Surveillance after resection for colorectal cancer. Cancer. 2013;119:1235-1242.
    1. Riera R, Bagattini AM, Pacheco RL, Pachito DV, Roitberg F, Ilbawi A. Delays and disruptions in cancer health care due to COVID-19 pandemic: systematic review. JCO Glob Oncol. 2021;7:311-323.
    1. Patt D, Gordan L, Diaz M, et al. Impact of COVID-19 on cancer care: how the pandemic is delaying cancer diagnosis and treatment for American seniors. JCO Clin Cancer Inform. 2020;4:1059-1071.
    1. Fillon M. Cancer treatment delays caused by the COVID-19 pandemic may not hinder outcomes. CA Cancer J Clin. 2021;71:3-6.
    1. Parikh RB, Takvorian SU, Vader D, et al. Impact of the COVID-19 pandemic on treatment patterns for patients with metastatic solid cancer in the United States. J Natl Cancer Inst. 2022;114:571-578.
    1. Minami CA, Kantor O, Weiss A, Nakhlis F, King TA, Mittendorf EA. Association between time to operation and pathologic stage in ductal carcinoma in situ and early-stage hormone receptor-positive breast cancer. J Am Coll Surg. 2020;231:434-447.e2.
    1. Thomson CA, Overholser LS, Hebert JR, Risendal BC, Morrato EH, Wheeler SB. Addressing cancer survivorship care under COVID-19: perspectives from the Cancer Prevention and Control Research Network. Am J Prev Med. 2021;60:732-736.
    1. Jammu AS, Chasen MR, Lofters AK, Bhargava R. Systematic rapid living review of the impact of the COVID-19 pandemic on cancer survivors: update to August 27, 2020. Support Care Cancer. 2021;29:2841-2850.
    1. Beebe-Dimmer JL, Lusk CM, Ruterbusch JJ, et al. The impact of the COVID-19 pandemic on African American cancer survivors. Cancer. 2022;128:839-848.
    1. Rentscher KE, Zhou X, Small BJ, et al. Loneliness and mental health during the COVID-19 pandemic in older breast cancer survivors and noncancer controls. Cancer. 2021;127:3671-3679.
    1. Islam JY, Vidot DC, Camacho-Rivera M. Evaluating mental health-related symptoms among cancer survivors during the COVID-19 pandemic: an analysis of the COVID impact survey. JCO Oncol Pract. 2021;17:e1258-e1269.
    1. Thom B, Benedict C, Friedman DN, Watson SE, Zeitler MS, Chino F. Economic distress, financial toxicity, and medical cost-coping in young adult cancer survivors during the COVID-19 pandemic: findings from an online sample. Cancer. 2021;127:4481-4491.
    1. Dietz JR, Moran MS, Isakoff SJ, et al. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. The COVID-19 Pandemic Breast Cancer Consortium. Breast Cancer Res Treat. 2020;181:487-497.
    1. Jazieh AR, Chan SL, Curigliano G, et al. Delivering cancer care during the COVID-19 pandemic: recommendations and lessons learned from ASCO Global Webinars. JCO Glob Oncol. 2020;6:1461-1471.
    1. Hollander JE, Carr BG. Virtually perfect? Telemedicine for Covid-19. N Engl J Med. 2020;382:1679-1681.
    1. Chan RJ, Crichton M, Crawford-Williams F, et al. The efficacy, challenges, and facilitators of telemedicine in post-treatment cancer survivorship care: an overview of systematic reviews. Ann Oncol. 2021;32:1552-1570.
    1. Silver JK, Baima J, Mayer RS. Impairment-driven cancer rehabilitation: an essential component of quality care and survivorship. CA Cancer J Clin. 2013;63:295-317.
    1. Kent EE, Ambs A, Mitchell SA, Clauser SB, Smith AW, Hays RD. Health-related quality of life in older adult survivors of selected cancers: data from the SEER-MHOS linkage. Cancer. 2015;121:758-765.
    1. van Leeuwen M, Husson O, Alberti P, et al. Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire. Health Qual Life Outcomes. 2018;16:114.
    1. Wu HS, Harden JK. Symptom burden and quality of life in survivorship: a review of the literature. Cancer Nurs. 2015;38:E29-E54.
    1. Stanton AL, Rowland JH, Ganz PA. Life after diagnosis and treatment of cancer in adulthood: contributions from psychosocial oncology research. Am Psychol. 2015;70:159-174.
    1. Smith TG, Castro KM, Troeschel AN, et al. The rationale for patient-reported outcomes surveillance in cancer and a reproducible method for achieving it. Cancer. 2016;122:344-351.
    1. Han X, Robinson LA, Jensen RE, Smith TG, Yabroff KR. Factors associated with health-related quality of life among cancer survivors in the United States. JNCI Cancer Spectr. 2021;5:pkaa123.
    1. Rock CL, Thomson CA, Sullivan K, et al. American Cancer Society nutrition and physical activity guideline for cancer survivors. CA Cancer J Clin. Published online March 16, 2022.
    1. Parikh RB, Kirch RA, Smith TJ, Temel JS. Early specialty palliative care-translating data in oncology into practice. N Engl J Med. 2013;369:2347-2351.
    1. Osagiede O, Colibaseanu DT, Spaulding AC, et al. Palliative care use among patients with solid cancer tumors: a National Cancer Data Base study. J Palliat Care. 2018;33:149-158.
    1. Yabroff KR, Mariotto A, Tangka F, et al. Annual Report to the Nation on the Status of Cancer, part 2: patient economic burden associated with cancer care. J Natl Cancer Inst. 2021;26:djab192.
    1. Nathan PC, Henderson TO, Kirchhoff AC, Park ER, Yabroff KR. Financial hardship and the economic effect of childhood cancer survivorship. J Clin Oncol. 2018;36:2198-2205.
    1. Zheng Z, Jemal A, Han X, et al. Medical financial hardship among cancer survivors in the United States. Cancer. 2019;125:1737-1747.
    1. Demark-Wahnefried W, Rogers LQ, Alfano CM, et al. Practical clinical interventions for diet, physical activity, and weight control in cancer survivors. CA Cancer J Clin. 2015;65:167-189.
    1. National Cancer Institute. Cancer Trends Progress Report. National Cancer Institute, National Institutes of Health, US Department of Health and Human Services; 2019. Accessed May 7, 2019.
    1. Westmaas JL, Alcaraz KI, Berg CJ, Stein KD. Prevalence and correlates of smoking and cessation-related behavior among survivors of ten cancers: findings from a nationwide survey nine years after diagnosis. Cancer Epidemiol Biomarkers Prev. 2014;23:1783-1792.
    1. Ornstein KA, Kelley AS, Bollens-Lund E, Wolff JL. A national profile of end-of-life caregiving in the United States. Health Aff (Millwood). 2017;36:1184-1192.
    1. Applebaum AJ, Breitbart W. Care for the cancer caregiver: a systematic review. Palliat Support Care. 2013;11:231-252.
    1. DuBenske LL, Gustafson DH, Namkoong K, et al. CHESS improves cancer caregivers' burden and mood: results of an eHealth RCT. Health Psychol. 2014;33:1261-1272.
    1. Waldron EA, Janke EA, Bechtel CF, Ramirez M, Cohen A. A systematic review of psychosocial interventions to improve cancer caregiver quality of life. Psychooncology. 2013;22:1200-1207.
    1. Schroeder MC, Gao X, Lizarraga I, Kahl AR, Charlton ME. The impact of Commission on Cancer accreditation status, hospital rurality and hospital size on quality measure performance rates. Ann Surg Oncol. 2022;29:2527-2536.
    1. Fedewa SA, Ward EM, Stewart AK, Edge SB. Delays in adjuvant chemotherapy treatment among patients with breast cancer are more likely in African American and Hispanic populations: a national cohort study 2004-2006. J Clin Oncol. 2010;28:4135-4141.
    1. Bhargava A, Du XL. Racial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph node-positive, operable breast cancer. Cancer. 2009;115:2999-3008.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅